Please login to the form below

Not currently logged in
Email:
Password:

Novimmune appoints Guillaume de Sampaïo

He brings experience from Roche, Novartis and Actelion to the Swiss biotech 

Swiss biotech Novimmune has appointed Guillaume de Sampaïo as global head of project management in a role that will also see him sit on its senior management team.

De Sampaïo has 15 years experience in life sciences, having previously served at the likes of Roche, Novartis and Actelion.

Prior to joining Novimmune he served at Danish biotech firm Forward Pharma, where he created and managed its clinical development group.

During that time he contributed to the development of the company's clinical trial portfolio and the facilitation of its successful US IPO during 2014. 

Novimmune chairman and CEO Eduard Holdener said: “With the progression of our R&D pipeline, project management becomes increasingly a crucial element in supporting our growth strategy. 

“Guillaume de Sampaïo will help us to further advance Novimmune as we move closer to the market with our lead program, NI-0501.”

30th November 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics